Author:
Tarafdar Nawar,Sachdeva Muskaan,Savinova Iryna,Lytvyn Yuliya,Maliyar Khalad,Georgakopoulos Jorge R.,Mufti Asfandyar,Yeung Jensen
Reference4 articles.
1. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management;Muntyanu;J Cutan Med Surg,2021
2. OCEBM Levels of Evidence Working Group = Jeremy Howick, Iain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard and Mary Hodgkinson.
3. Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review;De Bock;Case Rep Dermatol,2018
4. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline;Brahmer;J Clin Oncol,2018